A survey was conducted to determine the role of ambulatory care pharmacists in the care of patients with chronic kidney disease (CKD). Methods. Data from a survey of ambulatory care pharmacists in the treatment and management of patients with CKD were collected. A 22-item anonymous survey was sent to 1028 potential respondents in January 2004. Only pharmacists indicating routine provision of care to patients with risk factors for the development of CKD or with stages 1-4 of CKD were included in the analysis. Additional questions surveyed the timeliness and frequency of nephrology referrals and the pharmacists' familiarity with National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines. Results. Of 1028 surveys, 535 were completed and returned. Only respondents who provided care in an outpatient setting to geriatric patients and patients with diabetes mellitus, hypertension, or decreased creatinine clearance were included in the analysis (n = 388). Initial assessment of CKD was performed by 85% of the surveyed pharmacists. Over one third of the pharmacists made nephrology referrals. However, even pharmacists who had a high percentage of patients with a known risk for CKD infrequently screened for kidney dysfunction, and only a small portion monitored the areas recommended by NFK-K/DOQI. The respondents' familiarity with the NFK-K/DOQI guidelines indicated that 7% were very familiar, 45% were somewhat familiar, 34% were not very familiar, 13% were not at all familiar, and 1% did not respond. Conclusion. The ambulatory care pharmacists surveyed were not consistently involved in the routine monitoring of common complications of CKD.
Purpose.
A survey was conducted to determine the role of ambulatory care pharmacists in the care of patients with chronic kidney disease (CKD). Methods. Data from a survey of ambulatory care pharmacists in the treatment and management of patients with CKD were collected. A 22-item anonymous survey was sent to 1028 potential respondents in January 2004. Only pharmacists indicating routine provision of care to patients with risk factors for the development of CKD or with stages 1-4 of CKD were included in the analysis. Additional questions surveyed the timeliness and frequency of nephrology referrals and the pharmacists' familiarity with National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines. Results. Of 1028 surveys, 535 were completed and returned. Only respondents who provided care in an outpatient setting to geriatric patients and patients with diabetes mellitus, hypertension, or decreased creatinine clearance were included in the analysis (n = 388). Initial assessment of CKD was performed by 85% of the surveyed pharmacists. Over one third of the pharmacists made nephrology referrals. However, even pharmacists who had a high percentage of patients with a known risk for CKD infrequently screened for kidney dysfunction, and only a small portion monitored the areas recommended by NFK-K/DOQI. The respondents' familiarity with the NFK-K/DOQI guidelines indicated that 7% were very familiar, 45% were somewhat familiar, 34% were not very familiar, 13% were not at all familiar, and 1% did not respond. Conclusion. The ambulatory care pharmacists surveyed were not consistently involved in the routine monitoring of common complications of CKD. 2 and an additional 12 million with evidence of microalbuminuria. 1 The USRDS reported that the size of the Medicare population with CKD grew 146% between 1992-93 and 2002-03. 1 The economic effect of CKD is also tremendous and demands better treatment strategies be developed. In 2003, the federal government spent $18.1 billion for the care of patients with ESRD. 1 This affects many levels of society and supports the growing need to address CKD in its earliest stages.
The complications of CKD have been well established, but the care and treatment associated with the complications are currently lacking. Numerous studies document the poor quality of care that patients with CKD receive. [2] [3] [4] [5] [6] Israni et al. 3 investigated the management of CKD in an academic primary care clinic. The results showed suboptimal care in the areas of blood pressure control, use of angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs), identifi cation of proteinuria, and the number of patients referred to nephrologists. In patients with a mean creatinine clearance (CL cr ) of 39 mL/min, only 41% received an ACEI or ARB, only 54% had urinalysis performed, and only 21% had been referred to a nephrologist. Kausz et al. 6 also examined the care received by patients with CKD. Over 4000 patients were followed between October 1, 1994, and September 30, 1998. The average serum creatinine concentration of the patients was 3.2 mg/dL; the average estimated GFR was 22 mL/min. Only 18% and 15% had iron concentrations and serum parathyroid hormone concentrations measured, respectively. The percent of patients with a mean hematocrit of less than 30% was 38%. In addition, 55% did not have a proper calcium-phosphate balance. 6 While specifi c monitoring guidelines can help the health care provider assess the progression of CKD, the patient may also need specialized nephrology care to adequately prepare for renal replacement therapy. Many patients begin and continue care with a health care provider who is not a nephrologist. Prospective trials have determined an association with early nephrologist referral and improved outcomes, although these trials have not been randomized. [7] [8] [9] The role of the pharmacist in referring patients to nephrologists has not been well studied to date.
There are not much research and data on the pharmacist's contribution in the care of patients with CKD who are not yet dependent on dialysis, and the pharmacist's role has not been clearly established. Ambulatory care pharmacists are well positioned to care for patients who are seen on a regular basis. The potential for continuity of care provides the pharmacist an opportunity to identify and monitor signs of early disease in vulnerable patients with diabetes mellitus, hypertension, or decreased CL cr . The primary objective of this project was to determine what the role of a specifi c group of ambulatory care pharmacists was in the care of patients with CKD.
Methods
A survey was created to investigate the role of ambulatory care pharmacists in the treatment and management of patients with CKD. A national sample of pharmacists who self-identifi ed themselves as ambulatory care pharmacists through membership in the Ambulatory Care Practice and Research Network of the American College of Clinical Pharmacy was surveyed. The project was approved and received exempt status from informed consent by the local institutional review board (IRB). A cover letter, a 22-item anonymous survey, and a self-addressed, stampedreturn envelope were sent to 1028 potential respondents through the U.S. Postal Service in January 2004. The respondents were requested to return the survey within two weeks of receipt. No reminder notices or incentives for participation were provided. Only pharmacists indicating routine provision of care to patients with risk factors for development of CKD (e.g., hypertension, diabetes, and advanced age) or with stages 1-4 of CKD (as subjectively reported by these pharmacists) were included in the analysis. The survey included questions regarding the frequency of monitoring for anemia and calcium and phosphorus homeostasis, and respondents were asked to provide an estimate of the percentage of patients under their care with CKD, defi ned by a CL cr of less than 60 mL/min. These questions were designed to assess pharmacists' involvement in the screening and management of anemia and renal osteodystrophy of CKD. Additional questions surveyed the timeliness and frequency of nephrology referrals and pharmacists' overall familiarity with all published National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines. Predefi ned subgroup analyses were performed to assess the relationship of the provision of pharmaceutical care to CKD patients and the status of board certifi cation by the Board of Pharmaceutical Specialties (BPS), the highest level of formal pharmacy training completed, and the number of CKD patients managed as a percentage of the total number of patients managed by the responding pharmacist.
Survey data were entered into a Microsoft Access database (Microsoft Inc., Redmond, WA), and the comparative analysis of the prespecifi ed subgroups was completed using Graphpad InStat, version 3.0 (Graphpad Software, San Diego, CA). Comparisons of nominal data were conducted using Fisher's exact test or the chi-square test for independence, and comparisons of continuous data were conducted using an unpaired t test and one-way analysis of variance. Alpha values of less than 0.05 were considered to be statistically signifi cant.
Results
Of 1028 surveys, 535 were completed and returned for a survey response rate of 52%. Only respondents indicating that they provided care in an outpatient setting to geriatric patients and patients with diabetes, hypertension, or decreased CL cr were included in the analysis. The results are based on the 388 surveys that fulfi lled the preceding inclusion criteria.
Survey respondent demographics. Ambulatory care clinics were the primary patient care setting of 298 respondents (77%). The average time of practice in an outpatient setting was 5.6 years, and the majority of respondents participated in less than 10 direct patient encounters per day (n = 228, 59%). Thirty-eight percent (n = 149) of the respondents were certifi ed by BPS, and 49% (n = 190)
Am J Health-Syst Pharm-Vol 63 Nov 1, 2006 had completed a specialty residency as the highest level of pharmacy training. Survey responses were received from 45 of the 50 states as well as Puerto Rico and Canada. Survey responses indicated that 49% of respondents estimated that 10-25% of their patients had a CL cr of less than 60 mL/min, 38% estimated that 26-50% of their patients had a CL cr of less than 60 mL/min, and 8% estimated that greater than 50% of their patients had a CL cr of less than 60 mL/min.
Assessment and monitoring of kidney dysfunction. Initial assessment and monitoring of CKD were clinical functions performed by 85% of the surveyed pharmacists. Rates of assessment and monitoring of kidney function did not differ significantly according to BPS certification, highest level of pharmacy education, or the estimated percentage of patients with a CL cr of less than 60 mL/min (Table 1) .
Monitoring for anemia. In patients diagnosed with anemia secondary to CKD, pharmacists reported that their most common role in the disease state management of these patients was recommendation of appropriate therapy and monitoring of established therapy (41%). Other reported roles included recommending appropriate therapy only (without any subsequent monitoring responsibilities) (23%), managing therapy after initiation by another provider (12%), and no participating role in the management of the patient (9%). Monitoring hemoglobin and hematocrit levels in patients with CKD was routine for 24% of survey respondents. Self-reported rates of hematologic monitoring differed significantly according to respondent subgroup (Table 2) .
Monitoring calcium and phosphorus homeostasis. Monitoring of calcium and phosphate levels was reported to be routine by 16% of the survey respondents. The pharmacists who regularly assessed calcium and phosphorus homeostasis identified monitoring rates of monthly (16%), every three months (26%), every six months (29%), annually (8%), and other or no response (21%). Intact parathyroid hormone (i-PTH) levels were routinely monitored less frequently (4% of respondents) than other markers of renal osteodystrophy and secondary hyperparathyroidism. Table 2 . 
Assessment and Monitoring of Kidney

No. (%) Respondents
Assessment and Monitoring of Hemoglobin and Hematocrit
No. (%) Respondents
Routine monitoring of i-PTH levels was conducted quarterly, biannually, and annually by 36%, 29%, and 14% of respondents, respectively. None of the respondents reported monthly monitoring of i-PTH levels, while 21% of respondents reported either another rate of monitoring or did not provide a response. Fifty percent of the pharmacists involved in monitoring calcium-phosphorus and i-PTH levels on a routine basis reported that their primary role in patient care was recommending and monitoring therapy. Similar to the survey responses regarding monitoring for anemia, other roles included recommending appropriate therapy only (without subsequent monitoring) (36%), managing therapy after initiation by another provider (7%), or no response (7%).
Subgroup analysis demonstrated that signifi cantly more pharmacists with BPS certification routinely assessed and monitored calcium and phosphorus concentrations compared to pharmacists without BPS certifi cation (p = 0.03). No signifi cant differences in participation rates were identifi ed when responses were analyzed on the basis of pharmacy training or the percentage of patients treated who had a CL cr of less than 60 mL/min. No statistically significant differences were noted in the percentages of pharmacists in the prespecifi ed subgroups reporting routine monitoring of i-PTH levels (Table 3) .
Participation in nephrology referrals. Over one third of the responding pharmacists participated in nephrology referrals (Table 4) . Reported rates of nephrology referrals varied from daily (<1%) and weekly (5%) to monthly (20%). The modal response was less than monthly (65%). The extent and rate of nephrology referrals were not infl uenced by certifi cation status, residency training, or the CL cr of the patients.
Familiarity with NKF-K/DOQI guidelines. Respondents were re- Assessment and Monitoring of Serum Calcium, Phosphorus, and Intact Parathyroid Hormone (n = 388) 62 (16) 30 (20) 32 (13) 14 (21) 11 (11) 30 (16) 27 (14) 25 (17) 9 (28) 14 (4) 6 (4) 8 (3) 8 (4) 5 (3) 1 (3) 326 (84) 119 (80) 207 (87) 54 (79) 86 (89) 160 (84) 164 (86) 121 (83) 23 (72) 374 (96) 143 (96) 231 (97) 182 ( 
Participation in Nephrology Referrals (n = 388)
Participation in Nephrology Referrals
Variable
Yes No p
No. (%) Respondents
Am J Health-Syst Pharm-Vol 63 Nov 1, 2006 quested to provide an assessment of their level of familiarity, ranging from not at all familiar to very familiar, with current NKF-K/DOQI guidelines. Responses indicated that 7% of surveyed pharmacists were very familiar, 45% were somewhat familiar, 34% were not very familiar, and 13% were not at all familiar with the current guidelines. One percent of the returned surveys did not have a reported estimate.
Discussion
The NKF-K/DOQI guidelines offer health care professionals specific methods for patient care. In light of these guidelines, the primary objective of this investigation was to determine the current role of the ambulatory care pharmacists in the care of patients with CKD and to identify areas where pharmacists' roles could be expanded in relation to the NKF-K/DOQI. In comparison with previous studies, 3, 6 pharmacists were not providing significantly better care related to CKD than other health care disciplines. A majority of pharmacists initially assessed the presence of kidney dysfunction. Even pharmacists who had a significant percentage of patients with a known risk for CKD infrequently screened for kidney dysfunction, no more than other respondents. Only a small portion monitored the areas recommended by the NKF-K/DOQI, such as anemia and secondary hyperparathyroidism. Therefore, areas for potential expansion can be identified; two main areas are the pharmacist's roles in monitoring CKD-associated anemia and secondary hyperparathyroidism and in referring patients to a nephrologist. Our sample focused on patients who were at risk for or who already had CKD. The practice patterns noted in this study were especially troubling given the high-risk patient population of this study.
There were some limitations to the study. The first limitation is the sample size; a nonresponse bias may be present. The second limitation is the survey population. The survey results and any conclusions drawn need to be considered within the identified population and may not necessarily be characteristic of all ambulatory care pharmacists or of all pharmacists. In addition, the frequency of monitoring of the laboratory tests demonstrated in this study needs to be interpreted within the context of the routine patient follow-up. For example, patients with a CL cr of 30-60 mL/min require less frequent monitoring than patients with a CL cr of 15-29 mL/min.
The NKF-K/DOQI recommendation is that patients be referred to a nephrologist when their GFR falls below 30 mL/min. It may be possible that other members of the health care team, such as a nephrologist, may already be performing some of the monitoring discussed in our survey. If the patient has already seen a nephrologist, this could also explain why some pharmacists in this study may not have made referrals to nephrology.
Ambulatory care pharmacists are not the only health care professionals to encounter patients with CKD, but because of the previously discussed gap in current care, ambulatory care pharmacists are well positioned to affect the care of these patients. The current study indicates that pharmacists need to take more ownership of this opportunity to improve patient care with these patients. Because barely one half of respondents were familiar with NKF-K/DOQI guidelines, enhanced attempts at systematic pharmacist education of these guidelines is a reasonable first step in addressing this study's findings.
Conclusion
The ambulatory care pharmacists surveyed were not consistently involved in the routine monitoring of common complications of CKD.
